Lamictal XR Monotherapy: Will Ex-U.S. Data Invalidate Historical Comparison?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA reviewers cite issues with the study design GSK used in its sNDA, but still find evidence of efficacy for partial seizures.